• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 146-48-5 Price $40 / 20mg
    Catalog No.CFN90147Purity>=98%
    Molecular Weight354.44Type of CompoundAlkaloids
    FormulaC21H26N2O3Physical DescriptionCryst.
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Griffith University (Australia)
  • Warszawski Uniwersytet Medyczny (Poland)
  • Wroclaw Medical University (Poland)
  • Universidad de Antioquia (Colombia)
  • Universidade da Beira Interior (Germany)
  • University of Bonn (Germany)
  • Mahatma Gandhi University (India)
  • FORTH-IMBB (Greece)
  • Fraunhofer-Institut für Molekul... (Germany)
  • University of Zurich (Switzerland)
  • University of Otago (New Zealand)
  • More...
  • Package
    Featured Products

    Catalog No: CFN92376
    CAS No: 472-28-6
    Price: $388/5mg
    Viscidulin III

    Catalog No: CFN97488
    CAS No: 92519-91-0
    Price: $413/5mg
    Ganoderiol F

    Catalog No: CFN99244
    CAS No: 114567-47-4
    Price: $398/5mg
    Cyanidin-3-O-glucoside chloride

    Catalog No: CFN99740
    CAS No: 7084-24-4
    Price: $118/20mg
    Deapi-platycoside E

    Catalog No: CFN92355
    CAS No: 849758-42-5
    Price: $498/10mg
    Biological Activity
    Description: Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM. Yohimbine may augment extinction learning without significant side effects, and as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder. Yohimbine can be used as antagonistic agents against medetomidine-induced diuresis in healthy cats; it inhibits ATP-sensitive K+ channels in mouse pancreatic beta-cells.
    Targets: alpha 2-adrenergic receptor | ATPase | Potassium Channel
    In vitro:
    Br J Pharmacol. 1990 Sep;101(1):115-20.
    Phentolamine and yohimbine inhibit ATP-sensitive K+ channels in mouse pancreatic beta-cells.[Pubmed: 2282453 ]
    1. The effects of phentolamine and Yohimbine on adenosine 5'-triphosphate (ATP)-sensitive K+ channels were studied in normal mouse beta-cells.
    2. In the presence of 3 mM glucose, many ATP-sensitive K+ channels are open in the beta-cell membrane. Under these conditions, phentolamine inhibited 86Rb efflux from the islets. This inhibition was faster with 100 than with 20 microM phentolamine but its steady-state magnitude was similar with both concentrations. Yohimbine (20-100 microM) also inhibited the efflux rate but was not as potent as phentolamine. 3. In the presence of 6 mM glucose, most ATP-sensitive K+ channels are closed in the beta-cell membrane. Their opening by 100 microM diazoxide caused a marked acceleration of 86Rb efflux from the islets. This acceleration was almost entirely prevented by 20 microM phentolamine. It was barely affected by 20 microM Yohimbine and reduced by 50% by 100 microM Yohimbine. 4. ATP-sensitive K+ currents were studied in single beta-cells by the whole cell patch-clamp technique. Phentolamine (20-100 microM) caused a progressive but almost complete and irreversible inhibition of the current. The effects of Yohimbine were faster but smaller; the inhibition was still incomplete with 100 microM Yohimbine. 5. The increase in ATP-sensitive K+ current produced by 100 microM diazoxide was prevented by 100 microM phentolamine but only partially attenuated by 100 microM Yohimbine.
    6. It is concluded that phentolamine inhibits ATP-sensitive K+ channels in pancreatic beta-cells. This novel effect of phentolamine resembles that of hypoglycaemic sulphonylureas. It may account for previously unexplained effects of the drug. These observations also call for reinterpretation of many studies in which phentolamine was used as an allegedly specific blocker of alpha-adrenoceptors.
    In vivo:
    Biol Psychiatry. 2014 Jun 1;75(11):840-6.
    Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial.[Pubmed: 24237691]
    Preclinical and clinical trials suggest that Yohimbine may augment extinction learning without significant side effects. However, previous clinical trials have only examined adults with specific phobias. Yohimbine has not yet been investigated in the augmentation of exposure therapy for other anxiety disorders.
    Adults (n = 40) with a DSM-IV diagnosis of social anxiety disorder were randomized to placebo or Yohimbine HCl (10.8 mg) 1 hour before each of four exposure sessions. Outcome measures were collected at baseline, each treatment session, posttreatment, and 1-month follow-up. Yohimbine was well tolerated. Yohimbine augmentation, relative to placebo augmentation, resulted in faster improvement and better outcomes on self-report measures of social anxiety disorder severity (Liebowitz Social Anxiety Scale, d = .53) and depressed mood severity (Beck Depression Inventory, d = .37) but not on the clinician-rated measures (Clinical Global Impressions-Severity Scale, d = .09; Clinical Global Impressions-Improvement Scale, d = .25). Between-group differences on the Liebowitz Social Anxiety Scale were moderated by the level of fear reported at the end of an exposure exercise (end fear), such that the advantage of Yohimbine over placebo was only evident among patients who reported low end fear.
    The results provide moderate support for Yohimbine as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder, one that may be especially effective when coupled with successful exposure experiences. Beneficial effects for Yohimbine were readily evident for self-report measures but not for clinician-rated outcomes of social anxiety severity and improvement.
    Psychopharmacology (Berl). 2007 Dec;195(3):345-55.
    The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.[Pubmed: 17705061 ]
    Yohimbine is an alpha-2 adrenoreceptor antagonist that provokes stress- and anxiety-like responses in both humans and laboratory animals. In rats, Yohimbine increases operant alcohol self-administration and reinstates alcohol seeking. In this study, we assess whether these effects of Yohimbine are attenuated by systemic injections of the corticotrotropin-releasing factor 1 (CRF1) receptor antagonist antalarmin.
    In Exp. 1, we trained rats to lever press for alcohol solutions (12% w/v, 1 h/day) over several weeks; during training, the response requirement was increased from a fixed-ratio-1 (FR-1) to a fixed-ratio-3 (FR-3) reinforcement schedule. We then tested the effect of antalarmin (10 or 20 mg/kg) on Yohimbine (1.25 mg/kg)-induced increases in operant alcohol self-administration (FR-3 reinforcement schedule). Subsequently, we assessed the effect of antalarmin on Yohimbine-induced increases in plasma corticosterone levels in the previously self-administering rats. In Exp. 2, we trained the rats to self-administer alcohol as in Exp. 1, and after extinction of the alcohol-reinforced lever responding over 13 days, we tested antalarmin's effect on Yohimbine-induced reinstatement of alcohol seeking. Yohimbine increased operant alcohol self-administration and reinstated alcohol seeking after extinction. These effects of Yohimbine were attenuated by antalarmin. Antalarmin injections in the absence of Yohimbine had no effect on either operant alcohol self-administration or extinction responding. Antalarmin had no effect on Yohimbine-induced corticosterone release in alcohol-experienced rats.
    These results suggest that extrahypothalamic CRF1 receptors are involved in the effect of Yohimbine on operant alcohol self-administration and on relapse to alcohol seeking and support the notion that CRF1 receptor antagonists should be considered in alcohol addiction treatment.
    Yohimbine Description
    Source: The peels of Corynante yohimbe.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Arjunglucoside II

    Catalog No: CFN89144
    CAS No: 62369-72-6
    Price: $413/5mg
    Angelol H

    Catalog No: CFN91925
    CAS No: 83247-73-8
    Price: $338/5 mg

    Catalog No: CFN95107
    CAS No: 41347-45-9
    Price: $218/5mg

    Catalog No: CFN96266
    CAS No: 526-06-7
    Price: $188/20mg
    Sagittatoside A

    Catalog No: CFN90139
    CAS No: 118525-35-2
    Price: $413/5mg
    Carasinol B

    Catalog No: CFN95042
    CAS No: 777857-86-0
    Price: $333/5mg
    Buddlenoid A

    Catalog No: CFN95025
    CAS No: 142750-32-1
    Price: $368/5mg
    Neochlorogenic acid

    Catalog No: CFN97472
    CAS No: 906-33-2
    Price: $138/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.8214 mL 14.1068 mL 28.2135 mL 56.427 mL 70.5338 mL
    5 mM 0.5643 mL 2.8214 mL 5.6427 mL 11.2854 mL 14.1068 mL
    10 mM 0.2821 mL 1.4107 mL 2.8214 mL 5.6427 mL 7.0534 mL
    50 mM 0.0564 mL 0.2821 mL 0.5643 mL 1.1285 mL 1.4107 mL
    100 mM 0.0282 mL 0.1411 mL 0.2821 mL 0.5643 mL 0.7053 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Animal Research:
    Can J Vet Res. 2014 Oct;78(4):304-15.
    Antagonistic effects of atipamezole, yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats.[Pubmed: 25356000]
    This study aimed to investigate and compare the antagonistic effects of atipamezole, Yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats.
    Five cats were repeatedly used in each of the 9 groups. One group was not medicated. Cats in the other groups received 2 mg/kg BW xylazine intramuscularly, and saline (as the control); 160 μg/kg BW prazosin; or 40, 160, or 480 μg/kg BW atipamezole or Yohimbine intravenously 0.5 h later. Urine and blood samples were collected 10 times over 8 h. Urine volume, pH, and specific gravity; plasma arginine vasopressin (AVP) concentration; and creatinine, osmolality, and electrolyte values in both urine and plasma were measured. Both atipamezole and Yohimbine antagonized xylazine-induced diuresis, but prazosin did not. The antidiuretic effect of atipamezole was more potent than that of Yohimbine but not dose-dependent, in contrast to the effect of Yohimbine at the tested doses. Both atipamezole and Yohimbine reversed xylazine-induced decreases in both urine specific gravity and osmolality, and the increase in free water clearance. Glomerular filtration rate, osmolar clearance, and plasma electrolyte concentrations were not significantly altered. Antidiuresis of either atipamezole or Yohimbine was not related to the area under the curve for AVP concentration, although the highest dose of both atipamezole and Yohimbine increased plasma AVP concentration initially and temporarily, suggesting that this may in part influence antidiuretic effects of both agents. The diuretic effect of xylazine in cats may be mediated by α2-adrenoceptors but not α1-adrenoceptors.
    Atipamezole and Yohimbine can be used as antagonistic agents against xylazine-induced diuresis in clinically normal cats.
    Structure Identification:
    J AOAC Int. 2015 Mar-Apr;98(2):330-5.
    Characterization and quantitation of yohimbine and its analogs in botanicals and dietary supplements using LC/QTOF-MS and LC/QQQ-MS for determination of the presence of bark extract and yohimbine adulteration.[Pubmed: 25905738]
    The compound Yohimbine HCl has been restricted in Australia and categorized as a scheduled prescription drug in other parts of the world, including the United States where it is monographed as a drug in the U. S. Pharmacopeia. However, the bark of the yohimbe plant and its extract is considered a botanical that can be used as a dietary supplement in some parts of the world. For these reasons, methods to characterize the indole alkaloids of the bark and quantify Yohimbine and its analogs are presented using accurate mass LC/quadrupole time-of-flight (QTOF)-MS and triple quadrupole LC/MS, respectively.
    Samples were extracted with a QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method to characterize and quantify the indole alkaloids. With the LC/QTOF-MS in auto MS/MS mode the indole alkaloids were identified, and the isomeric response of each could be used to determine whether the actual bark or extract was in samples of dietary supplements and not adulteration with Yohimbine HCl. Analogs were identified and include yohimbic acid, methyl Yohimbine, and hydroxyl Yohimbine. Many isomers of each were also detected, but identified only by the number of chromatographic peaks. Quantification of Yohimbine and ajmalicine spiked extracts showed recoveries of 99 to 103% with RSD of 3.6% or lower and LODs of less than 100 ppt. Calibration of the two standards gave r(2) = 0.9999 in a range from 0.1 to 100 ppb.
    Dietary supplements quantified for these two compounds showed a range from not detected to 3x the amounts found in the bark.